ALD1613
ALD1613 is a potent neutralizing monoclonal antibody against adrenocorticotropic hormone (ACTH) . ALD1613 neutralizes ACTH-induced signaling and inhibits ACTH-induced cyclic AMP accumulation in a mouse adrenal cell line (Y1) via all five melanocortin receptors. ALD1613 significantly reduces plasma corticosterone levels in wild-type rats. ALD1613 can be used in the study of diseases associated with elevated ACTH levels[1].
Product Specifications
UNSPSC
12352203
Target
Melanocortin Receptor
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Smiles
[ALD1613]
References & Citations
[1]Andrew L Feldhaus, et al. ALD1613, a Novel Long-Acting Monoclonal Antibody to Control ACTH-Driven Pharmacology. Endocrinology. 2017 Jan 1;158 (1) :1-8.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
bs-6377R-Cy7 100 µL
Deformed Epidermal Autoregulatory Factor 1 Antibody, Cy7 Conjugated
Ask
View Details 
MBS1238126-01 0.02 mg (E-Coli)
Recombinant Yersinia pestis bv. Antiqua Molybdenum cofactor biosynthesis protein C (moaC)
Ask
View Details MBS1238126-02 0.1 mg (E-Coli)
Recombinant Yersinia pestis bv. Antiqua Molybdenum cofactor biosynthesis protein C (moaC)
Ask
View Details MBS1238126-03 0.02 mg (Yeast)
Recombinant Yersinia pestis bv. Antiqua Molybdenum cofactor biosynthesis protein C (moaC)
Ask
View Details